Bernd STOWASSER, Head of European Public Private Partnerships at SANOFI Germany will join BioFIT as a speaker and discuss latest issues on Big consortia: how they work and what are their outcomes.

Many companies and research institutes are getting more and more involved in consortia of different sizes in order to work together around specific questions they are all looking to find an answer to. Of course their organization can be very different depending on the number of partners involved and the questions addressed. But how can their outcomes be evaluated, knowing that what comes out is non-tangible knowledge which itself is later used in other R&D processes in order to obtain real results? Moreover, what type of guidance is necessary in order make them work and obtain successful outcomes?

Come learn more and discuss with our speakers on December 2nd at 9am.

Moderator: Hugh LAVERTY, Senior Scientific Project Manager, IMI – Innovative Medicines Initiative (BE)

Speakers:

  • Bernd STOWASSER, Head of Public Private Partnerships – External Innovation & Science Policy, Sanofi (DE)
  • Nicolas CARBONI, President, SATT Conectus Alsace (FR)
  • Jacky VONDERSCHER, President, Enyo Pharma (FR)
  • Bruno FRANCOIS, Clinical Lead COMBACTE Consortium, CHU Limoges/Inserm (FR)

Check full agenda

Check speakers

Members of the Steering Committee will meet again in Lille for an intensive journey of discussion on the content of the new program.

The Steering Committee is composed of international experts from pharma and biotech industries, TTO, research institutes as well as clusters and associations and investors.

Members have gathered around the table once, last November 25th 2013 in Lille, to define BioFIT program mainlines. The content is available here.

We look forward to meeting them again next February.

BioFIT’s prestigious Steering Committee have defined the content of the BioFIT 2014 Conference Program during their last meeting on November 25th, 2013.

BioFIT 2014 presents for this edition a dense and rich program organized around 3 main tracks and 12 sessions covering the future of public/private collaborations, dealmaking, financing and technology transfer issues and operating as a tool-box program for the various actors of this sector.

Plenary Session:

Accessing innovation: how to build long term partnerships?

Track 1:

Emerge, last and deliver: best practices in collaborative research

New models for bridging the gap from research to market
Big consortia: how do they work and what are their outcomes?
Emerge & happen: creative solutions to difficult problems in dealmaking
Make it work and last: how to best apply strategic alliance management
Looking ahead: how can big data be transformed into knowledge?
Biotech meets Medtech: towards an intensified collaboration

Track 2:

Early stage innovation: new routes to funding sources

Who will be funding the maturation phase in the future?
New practices from the VC industry in sourcing innovation
The road less traveled: new approaches to finance early stage innovation

Track 3:

Creative solutions for transferring innovation to market : TTO’s and industry’s new approaches

Driving innovation in Europe: using Horizon 2020 program
Scouting innovation: academia push and industry pull
The valuation process: do all stakeholders use the same criteria?

Full Program